Immunity to Candida

Oral Diseases

Volumn 8, Issue SUPPL. 2, 2002, Pages 69-75

  Fidel Jr , P L ^a,b  

^a LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b LOUISIANA STATE UNIV MEDICAL CENTER   (United States)

Author keywords

Candida albicans; HIV disease; Host defense mechanisms; Mucosal candidiasis; Oral candidiasis; Vaginal candidiasis

Indexed keywords

CYTOKINE; FUNGUS ANTIBODY; SALIVA PROTEIN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CANDIDA; CANDIDIASIS; CD4+ T LYMPHOCYTE; CELLULAR IMMUNITY; DISEASE COURSE; DISEASE PREDISPOSITION; EPITHELIUM CELL; FUNGUS IMMUNITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INNATE IMMUNITY; MYCOSIS; NEUTROPHIL; OROPHARYNX CANDIDIASIS; PRIORITY JOURNAL; REVIEW; VAGINA CANDIDIASIS; AIDS RELATED COMPLEX; COHORT ANALYSIS; COMPARATIVE STUDY; FEMALE; FUNGEMIA; IMMUNOLOGY; MOUTH MUCOSA; MUCOSA; MUCOSAL IMMUNITY; SERODIAGNOSIS; TH1 CELL; TH2 CELL; THRUSH; VAGINA;

ACQUIRED IMMUNODEFICIENCY SYNDROME; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTIBODIES, FUNGAL; CANDIDA; CANDIDIASIS, ORAL; CANDIDIASIS, VULVOVAGINAL; CD4-POSITIVE T-LYMPHOCYTES; COHORT STUDIES; CYTOKINES; DISEASE PROGRESSION; EPITHELIAL CELLS; FEMALE; FUNGEMIA; HIV INFECTIONS; HIV SERONEGATIVITY; HIV SEROPOSITIVITY; HUMANS; IMMUNITY, MUCOSAL; IMMUNITY, NATURAL; MOUTH MUCOSA; MUCOUS MEMBRANE; NEUTROPHILS; SALIVARY PROTEINS; TH1 CELLS; TH2 CELLS; VAGINA; IMMUNITY, INNATE; SALIVARY PROTEINS AND PEPTIDES;

EID: 18344403208     PISSN: 1354523X     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1601-0825.2002.00015.x     Document Type: Review

References (82)

1. Allen CM, Saffer A, Meister RK, Beck FM, Bradway S (1994). Comparison of a lesion-inducing isolate and a non-lesional isolate of Candida albicans in an immunosuppressed rat model of oral candidiasis. J Oral Pathol Med 23: 133-139.
2. Arancia G, Molinari A, Crateri P et al (1995). Noninhibitory binding of human interleukin-2-activated natural killer cells to the germ tube forms of Candida albicans. Infect Immun 63: 280-288.
3. Balish E, Filutowicz H, Oberley TD (1990). Correlates of cell-mediated immunity in Candida albicans-colnized gnotobiotic mice. Infect Immun 58: 107-113.
4. Beno DWA, Mathews HL (1992). Growth inhibition of Candida albicans by interleukin-2-activated splenocytes. Infect Immun 60: 853-863.
5. Beno DWA, Stover AG, Mathews HL (1995). Growth inhibition of Candida albicans hyphae by CD8+ lymphocytes. J Immunol 154: 5273-5281.
6. Black CA, Eyers FM, Russell A, Dunkley ML, Clancy RL, Beagley KW (1998). Acute neutropenia decreases inflammation associated with murine vaginal candidiasis but has no effect on the course of infection. Infect Immun 66: 1273-1275.
7. Burns DN, Tuomala R, Chang BH et al (1997). Vaginal colonization or infection with Candida albicans in human immunodeficiency virus-infected women during pregnancy and during postpartum period. Clin Infect Dis 24: 201-210.
8. Cantorna MT, Balish E (1990). Mucosal and systemic candidiasis in congenitally immunodeficient mice. Infect Immun 58: 1093-1100.
9. Casadevall A (1995). Antibody immunity and invasive fungal infections. Infect Immun 63: 4211-4218.
10. Cassone A, Boccanera M, Adriani DA, Santoni G, De Bernardis F (1995). Rats clearing a vaginal infection by Candida albicans acquire specific, antibody-mediated resistance to vaginal infection. Infect Immun 63: 2619-2624.
11. Cenci E, Mencacci A, Spaccapelo R et al (1995). T helper cell type 1 (Th1)- and Th2-like responses are present in mice with gastric candidiasis but protective immunity is associated with Th1 development. J Infect Dis 171: 1279-1288.
12. Chakir J, Cote L, Coulombe C, Deslauriers N (1994). Differential pattern of infection and immune response during experimental oral candidiasis in BALB/c and DBA/2 (H-2d) mice. Oral Microbiol Immunol 9: 88-94.
13. Clerici M, Shearer GM (1993). A TH1-TH2 switch is a critical step in the etiology of HIV infection. Immunol Today 14: 107-111.
14. Clerici M, Fusi ML, Ruzzante S et al (1997). Type 1 and type 2 cytokines in HIV infection - a possible role in apoptosis and disease progression. Ann Med 29: 185-188.
15. Clift RA (1984). Candidiasis in the transplant patient. Am J Medical 77 (Suppl. 4D): 34-38.
16. Colon M, Toledo N, Valiente CL, Rodriquez N, Yano N, Mathews HL (1998). Anti-fungal and cytokine producing activities of CD8+ T lymphocytes from HIV-1 infected individuals. AIDS Res 90: 21-26.
17. Coogan MM, Sweet SP, Challacombe SJ (1994). Immunoglobulin A (IgA), IgA1, and IgA2 antibodies to Candida albicans in whole and parotid saliva in human immunodeficiency virus infection and AIDS. Infect Immun 62: 892-896.
18. De Bernardis F, Boccanera M, Adriana D, Spreghini E, Santoni G, Cassone A (1997). Protective role of antimannan and anti-aspartyl proteinase antibodies in an experimental model of Candida albicans vaginitis in rats. Infect Immun 65: 3399-3405.
19. Deslauriers N, Cote L, Montplaisir S, De Repentigny L (1997). Oral carriage of Candida albicans in murine AIDS. Infect Immun 65: 661-667.
20. Djeu JY, Blanchard DK (1987). Regulation of human polymorphonuclear neutrophil (PMN) activity against Candida albicans by large granular lymphocytes via release of a PMN-activating factor. J Immunol 139: 2761-2767.
21. Duerr A, Sierra MF, Feldman J, Clarke LM, Ehlich I, Dehovitz J (1997). Immune compromise and prevalence of Candida vulvovaginitis in human immunodeficiency virus-infected women. Obstet Gynecol 90: 252-256.
22. Ehrensaft DV, Epstien RB, Sarpel S, Andersen BR (1979). Disseminated candidiasis in leukopenic dogs. Proc Soc Exp Biol Medical 160: 6-10.
23. Elin RJ, Edelin JB, Wolff SM (1974). Infection and immunoglobulin concentrations in Chediak-Higashi mice. Infect Immun 10: 88-91.
24. Ferrante A, Thong YH (1979). Requirement of heat-labile opsonins for maximal phagocytosis of Candida albicans. Sabouraudia 17: 293-297.
25. Fidel PL Jr, Lynch ME, Redondo-Lopez V, Sobel JD, Robinson R (1993). Systemic cell-mediated immune reactivity in women with recurrent vulvovaginal candidiasis (RVVC). J Infect Dis 168: 1458-1465.
26. Fidel PL Jr, Lynch ME, Sobel JD (1994). Effects of preinduced Candida-specific systemic cell-mediated immunity on experimental vaginal candidiasis. Infect Immun 62: 1032-1038.
27. Fidel PL Jr, Lynch ME, Sobel JD (1995a). Circulating CD4 and CD8 T cells have little impact on host defense against experimental vaginal candidiasis. Infect Immun 63: 2403-2408.
28. Fidel PL Jr, Lynch ME, Conaway DH, Tait L, Sobel JD (1995b). Mice immunized by primary vaginal C. albicans infection develop acquired vaginal mucosal immunity. Infect Immun 63: 547-553.
29. Fidel PL Jr, Wolf NA, KuKuruga MA (1996). T lymphocytes in the murine vaginal mucosa are phenotypically distinct from those in the periphery. Infect Immun 64: 3793-3799.
30. Fidel PL Jr, Luo W, Steele C, Chabain J, Baker M, Wormley FL (1999). Analysis of vaginal cell populations during experimental vaginal candidiasis. Infect Immun 67: 3135-3140.
31. Fratti RA, Ghannoum MA, Edwards JE Jr, Filler SG (1996). Gamma interferon protects endothelial cells from damage by Candida albicans by inhibiting endothelial cell phagocytosis. Infect Immun 64: 4714-4718.
32. Han Y, Cutler JE (1995). Antibody response that protects against disseminated candidiasis. Infect Immun 63: 2714-2719.
33. Han Y, Morrison RP, Cutler JE (1998). A vaccine and monoclonal antibodies that enhance mouse resistance to Candida albicans vaginal infection. Infect Immun 66: 5771-5776.
34. Hauman CH, Thompson IO, Theunissen F, Wolfaart P (1993). Oral carriage of Candida in healthy and HIV-seropositive persons. Oral Surg Oral Med Pathol 76: 570-572.
35. Hedges SR, Agace WW, Svanborg C (1995). Epithelial cytokine responses and mucosal cytokine networks. Trends Microbiol 3: 266-270.
36. Holm HW, Marwin RM (1967). Effects of surface active agents on the susceptibility of Swiss mice to Candida albicans. Mycopathol Mycol Appl 33: 186-192.
37. Imam N, Carpenter CCJ, Mayer KH, Fisher A, Stein M, Danforth SB (1990). Hierarchical pattern of mucosal Candida infections in HIV-seropositive women. Am J Medical 89: 142-146.
38. Kagaya K, Fukazawa Y (1981). Murine defense mechanism against Candida albicans infection. II. Opsonization, phagocytosis and intracellular killing of Candida albicans. Microbiol Immunol 25: 807-818.
39. Kaufmann SHE (1990). Heat shock proteins and the immune response. Immunol Today 114: 129-136.
40. Kelly KA, Rank RG (1997). Identification of homing receptors that mediate the recruitment of CD4 T cells to the genital tract following intravaginal infection with Chlamydia trachomatis. Infect Immun 65: 5198-5208.
41. Kirkpatrick CH (1989). Chronic mucocutaneous candidiasis. Eur J Clin Microbiol Infect Dis 8: 448-456.
42. Kirkpatrick CH, Rich RR, Bennett JE (1971). Chronic mucocutaneous candidiasis: model building in cellular immunity. Ann Intern Med 75: 955-978.
43. Klein RS, Harris CA, Small CB, Moll B, Lesser M, Friedland GH (1984). Oral candidiasis in high-risk patients as the initial manifestation of the acquired immunodeficiency syndrome. N Engl J Medical 311: 354-357.
44. Knight L, Fletcher J (1971). Growth of Candida albicans in saliva: stimulation by glucose associated with antibiotics, corticosteriods and diabetes mellitus. J Infect Dis 123: 371-377.
45. Landay AL, Clerici M, Hashemi F, Kessler H, Berzofsky JA, Shearer GM (1996). In vitro restoration of T cell immune function in human immunodeficiency virus-positive persons: Effects of interleukin (IL)-12 and anti-IL-10. J Infect Dis 173: 1085-1091.
46. Leigh JE, Steele C, Wormley FL Jr et al (1998). Th1/Th2 cytokine expression in saliva of HIV-positive and HIV-negative individuals: a pilot study in HIV-positive individuals with oropharyngeal candidiasis. J Acquir Immune Defic Syndr Hum Retrovirol 19: 373-380.
47. Leigh JE, Barousse M, Swoboda RK et al (2001). Candida-specific systemic cell-mediated immune reactivities in HIV-infected persons with and without mucosal candidiasis. J Infect Dis 183: 277-285.
48. Liljemark WF, Gibbons RJ (1973). Suppression of Candida albicans by human oral streptococci in gnotobiotic mice. Infect Immun 8: 846-849.
49. Macher AM (1988). The pathology of AIDS. Public Health Report 103: 246-254.
50. Mathur S, Virella G, Koistinen J, Borger EO, Mahvi TA, Fudenberg HH (1977). Humoral immunity in vaginal candidiasis. Infect Immun 15: 287-294.
51. Matthews RC, Burnie JP, Tabaqchali S (1984). Immunoblot analysis of the serological response in systemic candidosis. Lancet 2: 1415-1418.
52. Matthews RC, Burnie JP, Howat D, Rowland T, Walton F (1991). Autoantibody to heat-shock protein 90 can mediate protection against systemic candidosis. Immunology 74: 20-24.
53. Nagai Y, Takeshita N, Saku T (1992). Histopathologic and ultrastructural studies of oral mucosa with Candida infection. J Oral Pathol Med 21: 171-175.
54. Nielsen H, Bentsen KD, Hojtved L et al (1994). Oral candidiasis and immune status of HIV-infected patients. J Oral Pathol Med 23: 140-143.
55. Odden K, Schenck K, Hurlen B (1995). High numbers of T cells in gingiva from patients with human immunodeficiency virus (HIV) infection. J Oral Pathol Med 24: 413-419.
56. Odds FC (1988). Chronic mucocutaneous candidosis. Candida and Candidosis. University Park Press: Baltimore, MD, pp. 104-110.
57. Parr MB, Parr EL (1998). Mucosal immunity to herpes simplex virus type 2 infection in the mouse vagina is impaired by in vivo-depletion of T lymphocytes. J Virol 72: 2677-2685.
58. Paterson PY, Semo R, Blumenschein G, Swelstad J (1971). Mucocutaneous candidiasis, anergy and a plasma inhibitor of cellular immunity: reversal after amphotericin B therapy. Clin Exp Immunol 9: 595-602.
59. Polonelli L, De Bernardis F, Conti S et al (1994). Idiotypic intravaginal vaccination to protect against candidal vaginitis by secretory yeast killer toxin-like anti-idiotypic antibodies. J Immunol 152: 3175-3182.
60. Polonelli L, De Bernardis F, Conti S et al (1996). Human natural yeast killer toxin-like candidacidal antibodies. J Immunol 156: 1880-1885.
61. Quinti I, Palma C, Guerra EC et al (1991). Proliferative and cytotoxic responses to mannoproteins of Candida albicans by peripheral blood lymphocytes of HIV-infected subjects. Clin Exp Immunol 85: 1-8.
62. Reichart PA, Samaranayake LP, Philipsen HP (2000). Pathology and clinical correlates in oral candidiasis and its variants: a review. Oral Dis 6: 85-91.
63. Rhoads JL, Wright DC, Redfield RR, Burke DS (1987). Chronic vaginal candidiasis in women with human immunodeficiency virus infection. JAMA 257: 3105-3107.
64. Rogers TJ, Balish E (1980). Immunity to Candida albicans. Microbiol Rev 44: 660-682.
65. Romagnoli P, Pimpinelli N, Mori M, Reichart PA, Eversole LR, Ficarra G (1997). Immunocompetent cells in oral candidiasis of HIV-infected patients: an immunohistochemical and electron microscopical study. Oral Dis 3: 99-105.
66. Romani L, Mencacci A, Cenci E et al (1993). CD+ subset expression in murine candidiasis. J Immunol 150: 925-931.
67. Romani L, Mocci S, Bietta C, Lanfaloni L, Puccetti P, Bistoni F (1991). Th1 and Th2 cytokine secretion patterns in murine candidiasis: association of Th1 responses with acquired resistance. Infect Immun 59: 4647-4654.
68. Romani L, Puccetti P, Bistoni F (1996). Biological role of Th cell subsets in candidiasis. In: Romagnani S, ed. Th1 and Th2 Cells in Health and Disease. Karger: Farmington, CT, pp. 114-137.
69. Samaranayake LP (1992). Oral mycoses in HIV infection. Oral Surg Oral Med Pathol 73: 171-180.
70. Schuman P, Sobel JD, Ohmit S et al (1998). Mucosal candidal colonization and candidiasis in women with or at risk for human immunodeficiency virus infection. Clin Infect Dis 27: 1161-1167.
71. Shearer GM, Clerici M (1992). T helper cell immune dysfunction in asymptomatic, HIV-1-seropositive individuals: the role of TH1-TH2 cross-regulation. Cell Immunol 54: 21-43.
72. Sobel JD (1988). Pathogenesis and epidemiology of vulvovaginal candidiasis. Ann N Y Acad Sci 544: 547-557.
73. Sobel JD (1992). Pathogenesis and treatment of recurrent vulvovaginal candidiasis. Clin Infect Dis 14: S148-S153.
74. Spinillo A, Michelone G, Cavanna C, Colonna L, Capuzzo E, Nicola S (1994). Clinical and microbiological characteristics of symptomatic vulvovaginal candidiasis in HIV-seropositive women. Genitourin Med 70: 268-272.
75. Steele C, Ozenci H, Luo W, Scott M, Fidel PL Jr (1999). Growth inhibition of Candida albicans by vaginal cells from naive mice. J Medicalmycol 37: 251-260.
76. Steele C, Leigh JE, Swoboda RK, Ozenci H, Fidel PL, Jr (2001). Potentiel role for a carbohydrate moiety in anti-Candida activity of human oral epithelial cells. Infect Immun 69: 7091-7099.
77. Steidley KE, Thompson SH, McQuade MJ, Strong SL, Scheldt MJ, Van Dyle TE (1992). A comparison of T4:T8 lymphocyte ratio in the periodontal lesion of healthy and HIV-positive patients. J Periodontol 63: 753-756.
78. Sweet SP, Challacombe SJ, Naglik JR (1995). Whole and parotid saliva IgA and IgA-subclass responses to Candida albicans. HIV infection. Adv Exp Med 371: 1031-1034.
79. Taylor BN, Saavedra M, Fidel PL Jr (2000). Local Th1/Th2 cytokine production during experimental vaginal candidiasis. Med Mycol 38: 419-431.
80. Williams DW, Potts AJC, Wilson MJ, Matthews JB, Lewis MAO (1997). Characterisation of the inflammatory cell infiltrate in chronic hyperplastic candidosis of the oral mucosa. J Oral Pathol Med 26: 83-89.
81. + vaginal cells. Immunology 100: 300-308.
82. Yamamura M, Valdimarsson H (1977). Participation of C3 in intracellular of Candida albicans. Scand J Immunol 6: 591-594.